A 58-year-old man with gastric cancer receives cisplatin-based neoadjuvant chemotherapy. On day 2 post-chemotherapy, he develops delayed nausea and vomiting despite receiving ondansetron 8 mg IV on day 1. He has no abdominal distension or signs of gastric outlet obstruction. His renal function is normal (creatinine 0.9 mg/dL). Which antiemetic agent would be most appropriate to add to his current regimen to prevent further delayed CINV?

Explanation

## Management of Delayed CINV ### Clinical Context This patient is experiencing delayed CINV (nausea/vomiting on day 2 post-chemotherapy), which is a distinct entity from acute CINV. Cisplatin is one of the most highly emetogenic chemotherapy agents, and delayed emesis occurs in 70–90% of patients without prophylaxis. ### Why Aprepitant is Correct **Key Point:** NK₁ receptor antagonists (aprepitant) are the gold standard for prevention and treatment of delayed CINV, particularly after highly emetogenic agents like cisplatin. **High-Yield:** Aprepitant blocks substance P in the chemoreceptor trigger zone and nucleus tractus solitarius, the primary mediators of delayed CINV. It is superior to 5-HT₃ antagonists alone for delayed emesis. **Mechanism:** - Crosses blood–brain barrier and binds NK₁ receptors with high affinity - Substance P is the key neurotransmitter in delayed CINV (not serotonin) - Dosing: 125 mg on day 1 (within 1 hour of chemotherapy), then 80 mg on days 2 and 3 - Peak plasma levels: 4 hours; half-life: 40–50 hours ### Pathophysiology: Acute vs. Delayed CINV | Feature | Acute CINV (0–24 hrs) | Delayed CINV (24–120 hrs) | |---|---|---| | **Primary mediator** | Serotonin (5-HT) | Substance P (NK₁) | | **Site of action** | Chemoreceptor trigger zone | Nucleus tractus solitarius, vagal afferents | | **Best agent** | 5-HT₃ antagonist (ondansetron) | NK₁ antagonist (aprepitant) | | **Incidence** | 70–80% without prophylaxis | 70–90% without prophylaxis (cisplatin) | | **Severity** | Often severe | Often more severe than acute | **Clinical Pearl:** Delayed CINV is mediated by substance P, NOT serotonin. This is why 5-HT₃ antagonists alone are ineffective for delayed emesis — they block the wrong neurotransmitter. ### Optimal CINV Prophylaxis for Highly Emetogenic Chemotherapy (e.g., Cisplatin) ```mermaid flowchart TD A[Highly emetogenic chemotherapy]:::outcome --> B[Day 1 Prophylaxis]:::action B --> C["5-HT3 antagonist + Dexamethasone + Aprepitant"]:::action C --> D{CINV controlled?}:::decision D -->|Yes| E[Continue dexamethasone days 2-3]:::action D -->|No| F[Add aprepitant days 2-3]:::action E --> G[Aprepitant days 2-3 for delayed CINV]:::action G --> H[Optimal control achieved]:::outcome ``` **Mnemonic:** **SANK** for highly emetogenic chemotherapy: - **S** = Serotonin antagonist (ondansetron) - **A** = Aprepitant (NK₁ antagonist) - **N** = Neurokinin blocker (substance P pathway) - **K** = Korticosteroid (dexamethasone) ### Why Aprepitant is Superior for Delayed CINV - 5-HT₃ antagonists (granisetron, ondansetron) have minimal efficacy for delayed CINV because substance P, not serotonin, is the primary mediator - Aprepitant has a long half-life (40–50 hours), providing sustained NK₁ blockade over days 2–3 - Combination of aprepitant + dexamethasone is highly effective for delayed CINV **Tip:** If a patient develops delayed CINV despite ondansetron, the solution is NOT more 5-HT₃ antagonist — it is to switch to an NK₁ antagonist (aprepitant).